Supporting Pediatric <scp>RSV</scp> Clinical Trials Through Close Epidemiological Surveillance During the <scp>SARS</scp>‐<scp>CoV</scp>‐2 Pandemic
Clesrovimab, an extended half-life monoclonal antibody, aims to protect infants for an entire RSV season. The pandemic impacted RSV epidemiology and strategies were implemented to support clesrovimab trials. Near real-time monitoring of data showed minimal RSV activity in 2020. In 2021, RSV resurged early in some countries and was delayed in others, resulting in a change in trial enrollment strategy.
Authors
- Carmen Sofia Arriola
- Rennie Joshi (ORCID: https://orcid.org/0000-0002-7081-6967)
- Georges J. Nahhas (ORCID: https://orcid.org/0000-0001-8909-2228)
- Andrea Guerra (ORCID: https://orcid.org/0000-0001-6601-4964)
- Patricia Saddier
Institutions
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
Publication Details
- Journal
- Pharmacology Research & Perspectives
- Published
- 2025-05-01
- DOI
- https://doi.org/10.1002/prp2.70112
- Citations
- 2
- Primary Topic
- Respiratory viral infections research
- Type
- article
- Field-Weighted Citation Impact
- 2.71
Funders
- Merck